loading page

Isotype selection for antibody-based cancer therapy
  • +1
  • Dietmar Zaiss,
  • Sjef Verbeek,
  • Natasa Vukovic,
  • Andrea van Elsas
Dietmar Zaiss
University of Edinburgh
Author Profile
Sjef Verbeek
Toin University of Yokohama
Author Profile
Natasa Vukovic
University of Edinburgh
Author Profile
Andrea van Elsas
Aduro Biotech Europe
Author Profile


The clinical application of monoclonal antibodies (mAbs) revolutionised the field of cancer therapy as it enabled the successful treatment of previously untreatable types of cancer. Different mechanisms play a role in the anti-tumour effect of mAbs and both target engagement with the Fab arm as well as Fc-mediated effector functions contribute to the efficacy of treatment. Because Ig isotypes differ in their ability to bind to FcRs on immune cells as well as in their ability to activate complement, they differ in the immune responses they activate. Therefore, the choice of antibody isotype for therapeutic mAbs is dictated by its intended mechanism of action. Considering that clinical efficacy of many mAbs is currently achieved only in subsets of patients, optimal isotype selection and Fc optimisation during antibody development may represent an important step towards improved patient outcome. Here, we discuss the current knowledge of the therapeutic effector functions of different isotypes and Fc-engineering strategies to improve mAbs application.

Peer review status:ACCEPTED

17 Jul 2020Submitted to Clinical & Experimental Immunology
03 Aug 2020Submission Checks Completed
03 Aug 2020Assigned to Editor
13 Aug 2020Reviewer(s) Assigned
18 Sep 2020Review(s) Completed, Editorial Evaluation Pending
18 Sep 2020Editorial Decision: Revise Minor
16 Oct 20201st Revision Received
16 Oct 2020Reviewer(s) Assigned
29 Oct 2020Review(s) Completed, Editorial Evaluation Pending
29 Oct 2020Editorial Decision: Accept